Lord's Mark Industries schedules January 2027 healthcare launches

Lord's Mark Industries Limited has scheduled January 2027 commercial launches for sickle-cell and breast-cancer screening, while AI-based dialysis-machine exports are expected from late December 2026 after trials began in November. The November 14, 2026 roadmap also sets UK operations for February and targets US sales from March, subject to regulatory approval.

What will Lord's Mark Industries launch in January 2027?

Lord's Mark Industries plans to launch its sickle-cell screening product in January 2027, immediately after the expected issuance of its manufacturing licence. Lord's Mark Industries said all regulatory approvals for the project had been met, but identified the manufacturing licence as the remaining condition for commercial launch.

Lord's Mark Industries also plans to launch its breast-cancer screening device for mass screening in January 2027. Unlike the sickle-cell product, Lord's Mark Industries said the breast-cancer device had already cleared all regulatory approvals. The two January launches follow the securing of 26 additional medical-device manufacturing licences.

Lord's Mark Industries said its medical-device division had recorded higher sales and profitability across domestic and institutional channels. The November 14 update did not provide divisional revenue, profit, unit-sales or order-value data, so the financial scale of the January 2027 screening launches was not disclosed.

When will Lord's Mark Industries export dialysis machines?

Lord's Mark Industries expects commercial shipments of AI-based dialysis machines to start from the end of December 2026. Lord's Mark Industries said export orders had been secured and the machines were in final testing, after production began at its Bangalore facility and trials started in November 2026.

Lord's Mark Industries identified the UK, US, Africa, Nepal and Bangladesh as intended dialysis-machine export markets. The sales will be pure machine sales, according to the update. Lord's Mark Industries did not disclose order values, machine volumes, customer names, pricing or a precise December 2026 shipment date.

Lord's Mark Industries separately plans to launch a suite of AI-based medical devices for clinical use by physicians and general practitioners globally from February 2027. That broader February timetable is distinct from the dialysis programme, for which November 2026 trials and late-December 2026 commercial shipments were specified.

When will Lord's Mark Industries start UK, US and Caribbean sales?

Lord's Mark Industries expects product sales originating from India to begin in the UK in January 2027, followed by UK operations in February 2027. Lord's Mark Industries said its UK subsidiary had obtained the required UK approvals for its product range, including AI-based dialysis machines.

Lord's Mark Industries has established Lords Mark Industries Inc. in the US to set up a dedicated laboratory and manage exports of in-vitro diagnostics, or IVD, products and surgical products from India. Lord's Mark Industries targets US sales from March 2027, but stated that this start date depends on US FDA approval.

Lord's Mark Industries is also establishing pathology laboratories with local partners in the Caribbean and targets export sales there from March 2027. The update did not name Caribbean locations, partners, laboratory numbers, capital commitments or the planned test range. The disclosed overseas sequence is therefore January 2027 UK product sales, February UK operations, and March targets for US and Caribbean sales.

What capacity, research and clinical milestones has Lord's Mark Industries set?

Lord's Mark Industries said its institutional division served 10,000 customers, including hospitals, over the past two quarters and has a target of reaching 25,000 hospitals by March 2028. The target is 15,000 above the reported customer count, although Lord's Mark Industries did not state how many of the 10,000 customers were hospitals.

Lords Mark Microbiotech Ltd., a subsidiary, has opened more than 70 laboratories and collection centres across India. Lord's Mark Industries also added 10 professionals to its core research and development team and began construction of a third IVD manufacturing factory, which is slated to begin operating before March 2028.

Lord's Mark Industries said regulatory approval work for its CAR-T cancer treatment is under way, with final clinical trials scheduled to start in February 2027. Management expects trial reports to be published by December 2027 and advanced treatment centres to operate by June 2028. Lord's Mark Industries has also begun regulatory and clinical processes for the treatment in the US, UK and Europe.

Gut-testing products have received CDSCO approval and are ready for commercial rollout from December 2027, according to Lord's Mark Industries. The filing does not disclose the expected revenue from gut testing, the clinical-trial size for CAR-T, trial costs, or any product approval date for the CAR-T programme.

How do Lord's Mark Industries' financial results compare?

Lord's Mark Industries reported consolidated revenue of Rs 683.41 crore and consolidated profit after tax, or PAT, of Rs 50.44 crore for the six months ended September 30, 2026. Consolidated revenue exceeded standalone revenue by Rs 63.46 crore, while consolidated PAT was Rs 2.45 crore higher than standalone PAT for the same period.

On a standalone basis, Lord's Mark Industries reported PAT of Rs 47.99 crore for the six months ended September 30, 2026, compared with a loss of Rs 2.45 crore for the six months ended September 30, 2025. Standalone profit before tax was Rs 65.54 crore in the latest half-year, while the reported standalone PAT margin was 7.74% and the consolidated PAT margin was 7.38%.

The reported half-year financial results precede the late-December 2026 dialysis export expectation and the January-to-March 2027 product and geographic launch timetable. Lord's Mark Industries therefore did not report financial contributions from the planned screening launches, UK operations, US sales or Caribbean export programme in these September 2026 results.

Conclusion

Lord's Mark Industries has set a dated healthcare commercialisation roadmap spanning January 2027 screening launches, late-December 2026 dialysis-machine export expectations, and UK, US and Caribbean expansion steps through March 2027. The plan sits alongside 26 additional manufacturing licences, more than 70 laboratories and collection centres at Lords Mark Microbiotech Ltd., and Rs 683.41 crore in consolidated half-year revenue.

The next disclosed milestones are the sickle-cell manufacturing licence and screening launch in January 2027, UK product sales from India in January, UK operations and final CAR-T trials in February, and US and Caribbean sales targets in March. Management has also scheduled gut-testing rollout for December 2027, CAR-T trial reports by December 2027, the third IVD factory before March 2028, and treatment centres by June 2028.